Literature DB >> 7036710

Efficacy of diltiazem in angina on effort: a multicenter trial.

K F Hossack, P E Pool, P Steele, M H Crawford, A N DeMaria, L S Cohen, T A Ports.   

Abstract

During a multicenter study 57 patients with exercise-induced angina were evaluated with serial exercise testing to assess the efficacy of diltiazem, a calcium slow channel blocking agent, compared with a placebo. The study consisted of a 1 week single-blind placebo stabilization period followed by a double-blind triple crossover between diltiazem and placebo. Three dose levels were tested (120, 180 and 240 mg/day) in each patient. For the three time-related variables there was a significant dose-related response, with 240 mg/day being the most effective. The increases, over the washout placebo stabilization values, of the time-related variables for the 240 mg/day week compared with the corresponding placebo week were total duration of exercise 1.87 versus 1.05 minutes (p less than 0.002), time to onset of angina 1.81 versus 1.17 minutes (p less than 0.01) and time to appearance of 1 mm S-T segment depression 1.81 versus 1.01 minutes (p less than 0.002). Analysis of exercise variables indicated a significant reduction in heart rate, diastolic blood pressure, and pressure-rate product at submaximal exercise after administration of diltiazem. Diastolic blood pressure was significantly reduced at maximal exercise. Heart rate and pressure-rate product were unchanged at rest during submaximal or maximal exercise. Submaximal and maximal exercise S-T depression was not significantly altered by diltiazem. The reduction in pressure-rate product at submaximal exercise was a possible mechanism for the drug's beneficial effect in enhancing the three time-related variables.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7036710     DOI: 10.1016/s0002-9149(82)80013-1

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  15 in total

1.  Effects of diltiazem and isosorbide-5-mononitrate, alone and in combination, on patients with stable angina pectoris.

Authors:  H Emanuelsson; H Ake; M Kristi; R Arina
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

2.  Comparison of the antianginal efficacy of four calcium antagonists and propranolol in stable angina pectoris.

Authors:  M Picca; F Azzollini; A Cereda; G Pelosi
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

Review 3.  Diltiazem. A review of its pharmacological properties and therapeutic efficacy.

Authors:  M Chaffman; R N Brogden
Journal:  Drugs       Date:  1985-05       Impact factor: 9.546

4.  Attenuation by diltiazem of arterial baroreflex sensitivity in man.

Authors:  J F Giudicelli; A Berdeaux; A Edouard; F Lhoste; C Richer; C Thuillez; A Jacolot
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

5.  A comparison of nine calcium ion antagonists and propranolol: exercise tolerance, heart rate and ST-segment changes in patients with chronic stable angina pectoris.

Authors:  N S Khurmi; E B Raftery
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

6.  Antiischemic effect of intracoronary diltiazem on myocardial ischemia during PTCA.

Authors:  K Saito; H Nonogi; Y Goto; A Itoh; S Daikoku; S Miyazaki; K Haze
Journal:  Heart Vessels       Date:  1996       Impact factor: 2.037

7.  A comparison of diltiazem and atenolol in angina.

Authors:  D Wheatley
Journal:  Postgrad Med J       Date:  1985-09       Impact factor: 2.401

8.  Efficacy and safety of the 200-300 mg sustained release formulation of diltiazem administered once daily in patients with stable angina.

Authors:  B Trimarco; D Radzik; W Van Mieghem; E Neveux; A Wajman; P Attali; J Ponsonnaille
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

Review 9.  Calcium channel antagonists. Part II: Use and comparative properties of the three prototypical calcium antagonists in ischemic heart disease, including recommendations based on an analysis of 41 trials.

Authors:  L H Opie
Journal:  Cardiovasc Drugs Ther       Date:  1988-01       Impact factor: 3.727

Review 10.  Calcium channel antagonists. Part IV: Side effects and contraindications drug interactions and combinations.

Authors:  L H Opie
Journal:  Cardiovasc Drugs Ther       Date:  1988-07       Impact factor: 3.727

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.